NuvOx Closed Oversubscribed Convertible Notes
Tucson, AZ, September 18th, 2023 NuvOx Therapeutics (“NuvOx”) announced that it has closed an oversubscribed convertible notes round,...
top of page
The latest from NuvOx
Search
- Aug 30
NuvOx Announces Publication of Research Article in Cancer Research Communication
Tucson, AZ, August 28th, 2023 NuvOx Pharma announced publication of a research article, “Dodecafluoropentane Emulsion as a...
- Aug 14
NuvOx Announces BARDA Partnership for a Phase Ib ARDS/COVID Trial in Canada
Tucson, AZ, August 4th, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to...
- Jun 7
NuvOx Announces Glioblastoma Patient Treatment for Phase IIb RESTORE Trial
Tucson, AZ, May 30, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat...
- Apr 19
NuvOx Receives SPAN Grant
NuvOx Receives SPAN Grant to Conduct Late-stage Preclinical Studies of Putative Neuroprotectants Combined with Reperfusion Tucson, AZ, ...
- Mar 5
NuvOx Newly Issued US Patent
The issued patent has claims for methods of use of DDFPe for stroke treatment.
- Oct 11, 2022
- May 19, 2022
NuvOx Pharma Announces Issuance of a New Patent
Award of this patent broadens NuvOx’s extensive patent portfolio of perfluorocarbon-based therapeutic formulations to reverse hypoxia.
- May 9, 2022
NuvOx Appoints Dr. Robert King to SAB
Tucson, AZ, May 9th, 2022 – https://www.pr.com/press-release/861001 NuvOx Pharma, a clinical stage biotechnology company developing a...
- May 9, 2022
NuvOx Technology Featured in Prominent Peer Review Journal
Tucson, AZ, April 19, 2022 -- https://www.pr.com/press-release/859633 NuvOx Pharma’s technology, which is developed as a first-in-class...
- May 9, 2022
NuvOx Finalizes Facility Certification, Poising for Phase IIb Trials
Tucson, AZ, April 17, 2022 -- https://www.pr.com/press-release/859467 NuvOx Pharma, a clinical stage biotechnology company developing a...
- Mar 4, 2022
NuvOx Receives Notice from the Breakthrough DOD Award for its Immuno-Oncology Program
On February 11th, 2022,-- https://www.pr.com/press-release/859467 NuvOx Pharma received notice from the Department of Defense (DOD)...
- Feb 9, 2022
NuvOx to Participate in the BIO CEO Investor Conference
Tucson, AZ, February 10, 2022 – NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat...
- Jan 12, 2022
NuvOx to Present at Various Bio Forums in JPM Week Tucson, AZ, January 7, 2022
Tucson, AZ, January 7, 2022 – NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat...
- Oct 15, 2021
NuvOx Pharma Receives Phase I STTR Grant from NINDS for Preclinical Studies in Stroke
Tucson, AZ, October 12, 2021 --(PR.com)-- NuvOx Pharma, a Tucson based biotechnology company, has received a $478,000 NIH Phase I Small...
- Sep 9, 2021
NuvOx Pharma Generates Positive Preclinical Data Showing NanO2TM Boosts Efficacy of Immunotherapy
Tucson, AZ, September 09, 2021 --(PR.com)-- NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has generated positive...
- Jul 29, 2021
NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM
Tucson, AZ, July 29, 2021 --(PR.com)-- NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they...
- Jul 23, 2021
NuvOx Pharma Announces Issuance of New Patent Covering a New Method of Treating Cancer
Tucson, AZ, July 23, 2021 --(PR.com)-- NuvOx Pharma, a privately-held clinical-stage biotechnology company based in Tucson, Arizona, has...
- May 27, 2021
Tucson's NuvOx adds plant to make drugs in-house
A tandem of homegrown Tucson drug-development companies plans to make its own drugs for testing at a new manufacturing plant — and...
- Apr 30, 2021
NuvOx Completes Construction of Expanded Manufacturing Facility
A new GMP production facility including an ISO 5 cleanroom has been constructed and has initiated operations. Click here to read more...
bottom of page